Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06588894

Investigation of Motor Imagery Ability, Body Awareness and Cognitive Functions in Type 2 Diabetes Mellitus

Relationship Between Motor Imagery Ability, Body Awareness and Cognitive Functions in Individuals With Type 2 Diabetes Mellitus

Status
Recruiting
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Kutahya Health Sciences University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to examine the relationship between motor imagery skills, body awareness and cognitive functions in individuals with Type 2 Diabetes mellitus.

Detailed description

Motor imagery can be defined as a voluntary action simulation process that involves focusing intently on the cognitive components of motor tasks. In the literature, motor imagery is seen as a window opening to cognitive motor processes and especially motor control. Motor imagery is negatively affected in many diseases that affect the brain and brain functions, such as stroke, Parkinson, and multiple sclerosis, and motor imagery is frequently used in the rehabilitation of these diseases. Poor glycemic control in Type 2 Diabetes mellitus leads to deterioration in brain and cognitive functions. However, no study has been found on the effects of these disorders seen in Type 2 Diabetes mellitus on MI skills. Motor imagery is a mental practice that is becoming widespread in many areas. However, before considering using Motor imagery-based exercises as a therapy tool for patients, it is important to consider the extent to which patients cognitive impairments are related to their ability to form accurate motor images. For example, studies have found that patients with the lack of body awareness may not be able to produce kinesthetic images of motor movements. Body awareness is the tendency to pay attention to internal bodily sensations and stimuli and includes the cognitive, emotional, and perceptual abilities that constitute the person general self-awareness. Chronic diseases such as Type 2 Diabetes mellitus affect body awareness and image. Body awareness has been found to be associated with clinical parameters related to diabetes, such as fasting blood sugar and HbA1c levels and duration of diabetes in patients with Type 2 Diabetes mellitus. Changes in body awareness may disrupt the patient self-perception, leading to a poor clinical picture and a poor course of chronic diseases. Therefore, it is important to evaluate possible changes in internal body perception. To our knowledge, no study has been found in the literature examining the relationship between motor imagery skills of individuals with type 2 diabetes mellitus and body awareness and cognitive functions. The existence of this relationship may guide the use of motor imagery as a treatment method in individuals with Type 2 Diabetes mellitus whose body awareness and cognitive functions are impaired. Individuals who meet the inclusion criteria will be asked to sign an informed consent form. Then, demographic data of the individuals will be collected using a demographic data form. Individuals; motor imagery skills will be assessed using a mental stopwatch and mental rotation, body awareness will be assessed using the Body Awareness Questionnaire, and cognitive functions will be assessed using the Montreal Cognitive Assessment questionnaire.

Conditions

Interventions

TypeNameDescription
BEHAVIORALQuestionnaire and Physical ExamIndividuals motor imagery skills will be assessed using a mental chronometer and mental rotation, body awareness will be assessed using the Body Awareness Questionnaire, and cognitive functions will be assessed using the Montreal Cognitive Assessment questionnaire.
BEHAVIORALMotor Imagery AbilityIndividuals motor imagery skills will be assessed using a mental stopwatch and mental rotation, body awareness will be assessed using the Body Awareness Questionnaire, and cognitive functions will be assessed using theMontreal Cognitive Assessment questionnaire.

Timeline

Start date
2024-10-14
Primary completion
2026-11-14
Completion
2026-12-10
First posted
2024-09-19
Last updated
2026-03-10

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT06588894. Inclusion in this directory is not an endorsement.